Exploring How CQAs Affect the Function and Potency of AAV Gene Therapy Drug Products

Time: 1:30 pm
day: Conference Day Two


  • Delving into the intricacies of specific CQAs relevant to AAV gene therapy products
  • Exploring case studies demonstrating the correlation between CQAs and therapeutic outcomes
  • Assessing how specific CQAs, such as viral titer, capsid integrity, and transgene expression, directly influence the functional and potency aspects of AAV gene therapy